CUV - CLINUVEL PHARMACEUTICALS LIMITED

[Farleap11]

Couple of items:

 

1. Not sure whether its been posted before or not; however, the FDA Meeting: "Patient-Focussed drug Development for Vitiligo" programmed for yesterday to allow the FDA to obtain patient perspectives on the impact of Vitiligo on daily life, was postponed until further notice.

 

2. SHORT SELLING - Petition: There is provision advertised on the following shortman link - https://www.shortman.com.au/stock?q=CUV - for persons interested to sign a petition to Government supporting the banning the short selling of shares on the ASX. I get the impression Billy Boots might be interested in supporting this campaign! Anyone else ??

 

[Billy Boots]

As I said Mr Ironbark, just a thought unless you may have a better idea why CUV was up today by $2.10 and finshed up .04c REALLY? C'mon, pull the other leg.Have a nice day sir.

[bretto32]

The whole market fell off a cliff mate.

[Billy Boots]

Good man, I'm right onto it and thank you for your interest.

[Billy Boots]

Yes, but CUV ran right up to that cliff just to jump off, that ain't normal.

[ironbark222]

Billy boots my "rubbish" comment re your suggestion that Wolgen is shorting still stands.

[odi01]

https://www.livewiremarkets.com/wires/the-n...the-market-rout

[gerritbakker57]

Great find! US $ 300 million with only half of population in the US. It would scare the hell out of me if I was a Shorter!

[schlitzo]

Could someone in the know please explain the shorter's game with CUV?. One would think they would have collected when the SP was down at $13. On the contrary, the % is growing. With US sales just around the corner, I don't get it??? So far they haven't put a foot wrong so half expecting another tumble in the SP.

[PortugueseMan]

Reuters Health Information: Better Outcomes of Erythropoietic Protoporphyria Seen With Afamelanotide Use, by Will Boggs MD (March 30, 2020)

 

Some highlights:

 

• "Offer this to your patients when financially possible; it is a life changer," Dr. Janneke G. Langendonk of Erasmus MC, University Medical Center, in Rotterdam, told Reuters Health by email.

• Dr. Langendonk and colleagues investigated the outcomes of afamelanotide treatment in their single-center, single-arm prospective postauthorization safety and efficacy study of 117 patients with EPP.

• Patients received a controlled-release 16-mg subcutaneous implant of afamelanotide with an interval of at least 60 days and a maximum of four implants per year. In week 1, time spent outside rose a mean 1.85 hours per week with afamelanotide (P=0.06). By week 5, time spent outside had increased an average of 6.14 hours per week (P<0.001).

• The most common adverse events were nausea, fatigue/malaise, flushing and nausea with headache, all of which were self-limiting with a mean duration of one to two days directly after implantation. There were no treatment-related serious adverse events.

• Dr. Manisha Balwani of Icahn School of Medicine at Mount Sinai, in New York City, who studies porphyria but was not involved in the new work, told Reuters Health by email, "The most interesting finding is that patients responded to the drug regardless of baseline disease severity and that the effects improved over years of treatment." "Afamelanotide does not address the elevated protoporphyrin level or the ferrochelatase-enzyme deficiency," she explained. "It does not have any impact on liver disease in EPP."